Summary
Defects in DNA mismatch repair have been associated with both hereditary and sporadic forms of human cancer. Most of the attention has been focused on the incidence and genetics of mismatch repair defects, while little is known about the expression levels of the mismatch repair proteins and their significance in cancer cell biology. In this study, both the expression levels of hMSH2 and GTBP proteins were investigated by Western blotting in 20 untreated epithelial ovarian cancers. For these analyses, a commercial anti-hMSH2 monoclonal antibody and a newly generated mouse monoclonal anti-GTBP antibody were used. hMSH2 and GTBP proteins were detected by Western blotting in 19 out of 20 (95%) samples analysed and were found to be directly correlated (r = +0.51, P = 0.025). hMSH2 expression was significantly higher in ovarian cancer cells originating from solid tumours than from ascites (H = 4.5, P = 0.033), whereas GTBP content did not significantly differ according to the origin of cancer cells. No statistically significant differences were found in the distribution of hMSH2 and GTBP levels according to the age of the patients, grade of differentiation, histotype and extent of surgical debulking. The amount of hMSH2 protein was demonstrated to be significantly lower in stage IV than in stage III patients (H = 7.35, P = 0.007). Moreover, significantly lower hMSH2 levels were observed in non-responding patients compared to patients who achieved complete or partial response to cisplatin-based chemotherapy (H = 4.88, P = 0.027). Conversely, GTBP levels were not distributed differently according to stage of disease and chemotherapy response. Our study suggests a possible involvement of hMSH2 in ovarian cancer cell biology and susceptibility to chemotherapy. The possible biological and/or clinical role of GTBP expression in ovarian cancer patients remains to be elucidated.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Acharya, S., Wilson, T., Gradia, S., Kane, M. F., Guerrette, S., Marsischky, G. T., Kolodner, R. & Fishel, R. (1996). hMSH2 forms specific mispairs-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA 93: 13629–13634.
Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., Fishel, R. & Howell, S. B. (1996). Loss of DNA mismatch in acquired resistance to cisplatin. Cancer Res 56: 3087–3090.
Arzimanoglou, I. I., Lallas, T., Osborne, M., Barber, H. & Gilbert, F. (1996). Microsatellite instability differences between familial and sporadic ovarian cancers. Carcinogenesis 17: 1799–1804.
Branch, P., Hampson, R. & Karran, P. (1995). DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 55: 2304–2309.
Boyer, J. C., Umar, A., Risinger, J. I., Lipford, J. R., Kane, M., Yin, S., Barrett, J. C., Kolodner, R. D. & Kunkel, T. A. (1995). Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 55: 6063–6070.
Brown, R., Hirst, G. L., Gallagher, W. M., McIlwarth, A. J., Margison, G. P., van der Zee, A. G. J. & Anthoney, D. A. (1997). hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15: 45–52.
Dosch, J., Christmann, M. & Kaina, B. (1998). Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents. Carcinogenesis 19: 567–573.
Duckett, D. R., Drummond, J. T., Murchie, A. I. H., Reardon, J. T., Sancar, A., Lilley, D. M. J. & Modrich, P. (1996). Human MutSα recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d (GpG) adduct. Biochemistry 93: 6443–6447.
Eshleman, J. R. & Markowitz, S. D. (1995). Microsatellite instability in inherited and sporadic neoplasms. Curr Opin Oncol 7: 83–89.
Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D. & Howell, S. B. (1996). The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881–4886.
Glaab, W. & Tindall, K. R. (1997). Mutation rate at the hprt locus in human cancer cell lines with specific mismatch repair-gene defects. Carcinogenesis 18: 1–8.
Hawn, M. T., Umar, A., Carethers, J. M., Marra, G., Kunkel, T. A., Boland, C. R. & Koi, M. (1995). Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 55: 3721–3725.
King, B. L., Carcangiu, M. L., Carter, D., Kiechle, M., Pfisterer, J., Pfleiderer, A. & Kacinski, B. M. (1995). Microsatellite instability in ovarian neoplasms. Br J Cancer 72: 376–382.
Kutteh, W. H. & Kutteh, C. C. (1992). Quantitation of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in the effusions of ovarian epithelial neoplasms. Am J Obstet Gynecol 167: 1864–1869.
Leach, F. S., Polyak, K., Burrell, M., Johnson, K. A., Hill, D., Dunlop, G. M., Wyllie, A. H., Peltomaki, P., de la Chapelle, A., Hamilton, S. R., Kinzler, K. W. & Vogelstein, B. (1996). Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Cancer Res 56: 235–240.
Marra, G., Chang, C. L., Laghi, L. A., Chanhan, D. P., Young, D. & Boland, C. R. (1996). Expression of human MutS homolog 2 (hMSH2) protein in resting and proliferating cells. Oncogene 13: 2189–2196.
Mello, J. A., Acharya, S., Fishel, R. & Essigmann, J. M. (1996). The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 3: 579–589.
Modrich, P. & Lahue, R. (1996). Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem 65: 101–133.
Palombo, F., Gallinari, P., Iaccarino, I., Lettieri, T., Hughes, M., D’Arrigo, A., Truong, O. & Hsuan, J. J., Jiricny (1995). GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 268: 1912–1914.
Papadopoulos, N., Nicolaides, N. C., Liu, B., Parson, R., Lengauer, C., Palombo, F., D’Arrigo, A., Markowitz, S., Willson, J. K. V., Kinzler, K. W., Jiricny, J. & Vogelstein, B. (1995). Mutation of GTBP in genetically unstable cells. Science 268: 1915–1917.
Scambia, G., Ranelletti, F. O., Benedetti Panici, P., Piantelli, M., De Vincenzo, R., Bonanno, G., Ferrandina, G., Isola, G. & Mancuso, S. (1992). Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours. Eur J Cancer 28A: 1885–1889.
Serov, S. F. & Scully, R. (1973). Histological typing of ovarian tumours. In International Histological Classification of Tumours. World Health Organization: Geneva
Umar, A., Boyer, J. C., Thomas, D. C., Nguyen, D. C., Risinger, J. I., Boyd, J., Yonov, Y., Perucho, M. & Kunkel, T. A. (1994). Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J Biol Chem 269: 14367–14370.
Wilson, T. M., Ewel, A., Duguid, J. R., Ebel, J. N., Lescoe, M. K., Fishel, R. & Kelley, M. R. (1995). Differential cellular expression of the human MSH2 repair enzyme in small and large intestine. Cancer Res 55: 5146–5150.
World Health Organization (1979). WHO Handbook for Reporting Results of Cancer Treatment. WHO: Geneva
Yamada, M., O’Regan, E., Brown, R. & Karran, P. (1997). Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res 25: 491–495.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ercoli, A., Ferrandina, G., Raspaglio, G. et al. hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer. Br J Cancer 80, 1665–1671 (1999). https://doi.org/10.1038/sj.bjc.6690579
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690579
Keywords
This article is cited by
-
MiR-590-5p promotes cisplatin resistance via targeting hMSH2 in ovarian cancer
Molecular Biology Reports (2023)
-
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Journal of Hematology & Oncology (2019)
-
Survival of Patients with Ovarian Cancer due to a Mismatch Repair Defect
Familial Cancer (2005)
